Magellan Health — which is known for its digital innovation that help people struggling with various medical and behavioral conditions such as Substance Use Disorders (SUD) — is teaming-up with PEAR Therapeutics to measure clinical outcomes of its FDA-cleared prescription digital therapeutic, reSET.
The pilot program will enroll 250 patients with SUD and offer each patient a 12-week course of reSET therapy. The collaboration aims to examine patient abstinence and program retention through increased engagement and therapy adherence. The pilot will use advanced data analytics generated through the reSET therapy and accompanying clinician dashboards to provide technical support and clinical outreach to both treatment providers and their patients. Magellan will also work with PEAR to develop a series of publications highlighting the operational, economic and clinical results of this pilot program.
The pilot will help understand the value such FDA approved solutions bring to the healthcare market, as well as the operational requirements needed to support digital therapeutics in the future.
“This prescription digital therapeutic alternative offers physicians and members an evidence-based, non-drug treatment option, which is critical when you consider our nation’s current challenges with substance use,” Maria Lopes, M.D., chief medical officer at Magellan Rx Management, said in a statement. “Industry collaborations like this allow us to rethink the way treatment is delivered and offer practical solutions to meet the complex needs we face today.”
reSET is designed to be used in conjunction with standard outpatient treatment for substance use disorder related to stimulants, cannabis, cocaine, and alcohol. It combines patient-facing interventions and assessments via a mobile device, with clinician-facing dashboards and data analytics on the back-end. reSET has been shown in clinical studies to increase abstinence from a patient’s substances of abuse during treatment and increase patient retention in the outpatient treatment program. It provides access to self-reported substance use, triggers, cravings and outcomes to the patient’s medical provider.
“We believe that prescription digital therapeutics hold great promise in improving patient outcomes across a wide range of central nervous system disorders including psychiatry, neurology and pain, and will become a vital part of tomorrow’s treatment paradigm across all disease areas,” Corey McCann, M.D., Ph.D., president and CEO of PEAR Therapeutics, said in a statement. “Collaborating with a company like Magellan will help PEAR get this innovative solution to patients who need it most.”
According to the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 20.2 million adults have a type of SUD in the United States.